Myriad Genetics Inc. (MYGN) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Myriad Genetics Inc.

    NASDAQ: MYGN · Real-Time Price · USD
    6.90
    -0.07 (-1.00%)
    At close: Sep 10, 2025, 3:59 PM
    6.89
    -0.14%
    After-hours: Sep 10, 2025, 06:54 PM EDT

    Myriad Genetics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 837.6M 753.2M 678.4M 690.6M
    Cost of Revenue
    		 252.2M 236.2M 202M 197.6M
    Gross Profit
    		 585.4M 517M 476.4M 493M
    Operating Income
    		 -123.5M -257.4M -123.7M -48.7M
    Interest Income
    		 1.7M 2.5M 2.6M 700K
    Pretax Income
    		 -123.5M -262.2M -140.6M -57.1M
    Net Income
    		 -127.3M -263.3M -112M -27.2M
    Selling & General & Admin
    		 560M 572.9M 514.7M 599.8M
    Research & Development
    		 113.4M 88.7M 85.4M 81.9M
    Other Expenses
    		 35.5M 112.8M 600K n/a
    Operating Expenses
    		 708.9M 774.4M 600.1M 681.7M
    Interest Expense
    		 2.8M 2.9M 3.2M 6.6M
    Selling & Marketing Expenses
    		 284.1M n/a n/a n/a
    Cost & Expenses
    		 961.1M 1.01B 802.1M 879.3M
    Income Tax Expense
    		 3.8M 1.1M -28.6M -29.9M
    Shares Outstanding (Basic)
    		 90.6M 82.8M 80.58M 77.71M
    Shares Outstanding (Diluted)
    		 90.6M 82.8M 80.6M 78M
    EPS (Basic)
    		 -1.41 -3.18 -1.39 -0.35
    EPS (Diluted)
    		 -1.41 -3.18 -1.39 -0.35
    EBITDA
    		 -59.5M -186.1M -67.8M 14.1M
    EBIT
    		 -120.7M -259.3M -123.7M -48.7M
    Depreciation & Amortization
    		 61.2M 61.9M 55.9M 62.8M

    Add to Watchlist